PENG Block vs PENG Plus Periarticular Injection vs Periarticular Injection in Older Adults
Key facts
- Where
- Poznan, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 100 years old?
Source: NCT07327892, who can take part
Where in Poland
- Poznan University of Medical SciencesPoznan, PolandContact: Malgorzata Reysner, M.D. Ph.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Poznan University of Medical Sciences
- Trial code
- NCT07327892
- Record updated
- 1 July 2026
- Original description
Pain after hip surgery is common in older adults and may limit early mobilization, increase the need for opioid medications, and contribute to complications such as delirium, nausea, or prolonged hospital stay. Effective postoperative pain management that preserves muscle strength and supports early rehabilitation is especially important in this population.Read full original descriptionShow less
Comparison of Pericapsular Nerve Group (PENG) Block, PENG Block Plus Periarticular Injection, and Periarticular Injection Alone for Postoperative Pain Management in Older Adults Undergoing Hip Surgery: A Randomized Controlled Trial
Pain after hip surgery is common in older adults and may limit early mobilization, increase the need for opioid medications, and contribute to complications such as delirium, nausea, or prolonged hospital stay. Effective postoperative pain management that preserves muscle strength and supports early rehabilitation is especially important in this population.
Several analgesic strategies are currently used after hip surgery. Periarticular injection (PAI), administered by the surgeon during the procedure, is commonly used as part of standard care. The pericapsular nerve group (PENG) block is a newer ultrasound-guided regional anesthesia technique that targets the sensory nerves of the hip joint while sparing motor function. It may provide effective pain relief and facilitate early mobilization. However, it is unclear whether PENG block alone is superior to periarticular injection, and whether combining both techniques provides additional benefit.
The aim of this randomized controlled clinical study is to compare three postoperative analgesic strategies in older adults undergoing hip surgery: PENG block alone, PENG block combined with periarticular injection, and periarticular injection alone. Participants will be randomly assigned to one of three study groups.
The primary hypothesis is that regional anesthesia with a PENG block, either alone or combined with periarticular injection, will provide superior postoperative pain control compared with periarticular injection alone. A secondary hypothesis is that the combination of PENG block and periarticular injection will offer additional analgesic benefit compared with PENG block alone.
Outcomes assessed in this study will include postoperative pain intensity, need for additional pain medications, time to first mobilization, and the occurrence of adverse events relevant to older adults, such as hypotension, excessive sedation, or postoperative delirium.
The results of this study may help determine the most effective and practical analgesic strategy for hip surgery in older adults and support evidence-based optimization of postoperative pain management.
Inclusion: Age 65 years or older; Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty); ASA physical status I-III; Ability to communicate pain intensity using the NRS scale; Written informed consent obtained from the patient or legal representative.
Exclusion: History of chronic opioid use (daily opioids >30 days before surgery); Patients receiving another regional nerve block for hip surgery; Allergy, intolerance, or contraindication to any study medication: ropivacaine; Infection at or near the injection site; Severe hepatic or renal impairment; Cognitive impairment or delirium precluding reliable pain assessment; Coagulopathy (INR >1.5, platelets <100,000/µL) or current therapeutic anticoagulation that contraindicates regional anesthesia; Patient refusal or inability to provide informed consent; Pre-existing neurological deficit or neuropathy of the affected limb; BMI > 40 kg/m² (if you want to exclude for technical difficulty); Pregnancy or breastfeeding; Participation in another interventional clinical trial within 30 days.